Projects

AOCS is a national and international resource that researchers, with approved projects, can utilise for their research.  Further information on how to apply for access to AOCS data or biospecimens can be found  here.

 

Listed below are the details of projects that have been supported by AOCS to date.

Project Number Applicant’s Name Affiliation Title of Project
05/3 Ahmed Ashour Ahmed Hutchinson/MRC Research Centre Analysis of p53 mutation status of ovarian tumours
05/6 Adele Green Queensland Institute of Medical Research (QIMR) Quality of Life in Advanced Ovarian Cancer
05/7 Phyllis Butow Director Medical Psychology Research Unit, University of Sydney Quality of Life and psychosocial predictors of outcome in Ovarian Cancer
05/8 Richard Tothill Peter MacCallum Cancer Centre Expression profiling of mucinous tumours arising in the Ovary
06/2 Georgia Chenevix-Trench Queensland Institute of Medical Research (QIMR) Identification of low-risk susceptibility genes in the AOCS
06/3 Paul Pharoah University of Cambridge – Strangeways Research Laboratory A genome wide study to evaluate the association between germline genetic variation and disease risk in epithelial ovarian cancer
06/4 Phillippa O’Brien Garvan Institute of Medical Research Epigenetic markers of ovarian cancer
06/5 David Bowtell Peter MacCallum Cancer Centre Characterization of a cohort of AOCS women with a previous history of breast cancer
06/6 Alex Dobrovic Peter MacCallum Cancer Centre Validation of High Resolution Melting Analysis Using AOCS Samples
06/7 Robyn Ward St. Vincents Hospital Sydney & University of New South Wales The role of germline epimutations in ovarian cancer
07/1 David Bowtell Peter MacCallum Cancer Centre DoD – Project 1:  Molecular Subtype Analysis of Ovarian Cancer
07/2 Penny Webb Queensland Institute of Medical Research (QIMR) DoD – Project 2 – Determinants of Epithelial Ovarian Cancer – by Histologic Subtype & Tumour Behaviour
07/3 Georgia Chenevix-Trench Queensland Institute of Medical Research (QIMR) DoD – Project 3 – Low Risk Genes for Epithelial Ovarian Cancer
07/4 Adele Green & Penny Webb Queensland Institute of Medical Research (QIMR) Comparison of quality of Life and Chemotherapy End-Points in Advanced Ovarian Cancer
07/5 Penny Webb Queensland Institute of Medical Research (QIMR) The Insulin-like growth factor system, lifestyle and risk and prognosis of ovarian cancer
07/6 Michelle Haber Children’s Cancer Institute Australia for Medical Research Prognostic significance of ABCC/MRP transporter gene expression in Ovarian Cancer
07/7 Penny Webb Queensland Institute of Medical Research (QIMR) Folate and related micronutrients, folate metabolising genes and risk of ovarian cancer
07/8 Debbie Handolias Peter MacCallum Cancer Centre Molecular analysis of the P13K pathway in ovarian cancer and correlation with clinical and pathological parameters
07/9 Paul Scuffham Griffith University Economic assessment of treatment in advanced ovarian cancer (pilot study)
07/10 Mike Anglesio Peter MacCallum Cancer Centre High Resolution Study of Ovarian Clear Cell Carcinoma
07/11 Gillian Mitchell FCC, Peter MacCallum Cancer Centre Genetic Profiling in the Australian Ovarian Cancer Study
08/1 Martin Oehler Royal Adelaide Hospital Profiling of the Immunoproteome in early ovarian cancer
08/2 Wayne Tilley University of Adelaide / Hanson Institute Androgen receptor activity in normal and abnormal human ovarian function
08/3 David Bowtell Peter MacCallum Cancer Centre Mutation scanning by deep sequencing of ovarian cancer
08/4 Joellen Schildkraut Duke University Medical Centre Comprehensive evaluation of DNA repair pathways in Ovarian Cancer
08/5 Debbie Handolias Peter MacCallum Cancer Centre Molecular analysis of the P13K pathway in ovarian cancer and correlation with clinical and pathological parameters
08/6 Georgia Chenevix-Trench Queensland Institute of Medical Research (QIMR) Response of Chemotherapy in Ovarian Cancer
04/2 Dariush Etemadmoghadam Peter MacCallum Cancer Centre SNP Based CGH analysis
08/7 Anna deFazio Westmead Institute for Cancer Research – Westmead Millenium Institute Chemosensitising pathways in Ovarian Cancer
08/8 Penny Webb Queensland Institute of Medical Research (QIMR) Pooled analyses of epidemiologic risk factors and gene x environment interactions for ovarian cancer
08/9 David Bowtell Peter MacCallum Cancer Centre Analysis of the Ovarian Cancer Genome by deep sequencing
08/10 David Bowtell Peter MacCallum Cancer Centre AOCS Participation in The Cancer Genome Atlas (TCGA) project
08/11 Maria Kavallaris Children’s Cancer Institute Australia for Medical Research Targeting the Cytoskeleton in Cancer
08/12 Anna deFazio Westmead Institute for Cancer Research – Westmead Millennium Institute Molecular Pathways from Low Malignant Potential to Invasive Ovarian Cancer
08/13 Prue Cowin Peter MacCallum Cancer Centre Genomic analysis of primary epithelial ovarian cancers and patient-matched relapse ascites
08/14 Keiran Harvey Peter MacCallum Cancer Centre Is the Salvador-Warts-Hippo Pathway deregulated in human cancer?
08/15 David Huntsman British Columbia Cancer Agency A Novel Marker for Granulosa Cell Tumours
08/16 Pritinder Kaur Peter MacCallum Cancer Centre Pericytes: Prognostic indicators of aggressive recurrent carcinomas and accelerated tumour growth
08/17 David Bowtell Peter MacCallum Cancer Centre Detection of alternatively spliced genes and fusion genes in ovarian cancer using whole genome exon array data
08/18 Frances Balkwill Barts and The London Medical School A study evaluating the predictive value of pro-inflammatory cytokine pathway enrichment for response to targeted therapy in epithelial ovarian cancer
09/1 Kylie Gorringe Peter MacCallum Cancer Centre Meta-analysis of Ovarian Cancer Copy Number data
09/2 Ian Campbell Peter MacCallum Cancer Centre High resolution genetic analysis of putative ovarian cancer precursors
09/3 Penny Webb Queensland Institute of Medical Research (QIMR) Ovarian Cancer Patterns of Care Survey
09/4 David Bowtell Peter MacCallum Cancer Centre Analysis of methylation status in primary serous ovarian cancer and patient matched relapse ascites.
09/5 Keith Dunker Indiana University – Purdue University at Indianapolis Gene Signature and Biomarker development in Cancer and Toxicogenomics
09/6 Penny Webb Queensland Institute of Medical Research (QIMR) Epidemiology of endometrial cancer
09/7 David Bowtell Peter MacCallum Cancer Centre Validation of Candidate Genes
09/8 Georgia Chenevix-Trench Queensland Institute of Medical Research (QIMR) Patterns of methylation in BRCA1, BRCA2 and sporadic ovarian cancer – a pilot study
09/9 Ian Campbell Peter MacCallum Cancer Centre Next Generation Sequencing of Ovarian Carcinoma
09/10 David Bowtell Peter MacCallum Cancer Centre Molecular Features of “BRCA-ness”: an extension of Project #07/11 – Genotyping in the Australian Ovarian Cancer Study
09/11 David Bowtell Peter MacCallum Cancer Centre Siah2 Protein Expression in Ovarian Cancer
09/12 Robert Bast UT MD Anderson Cancer Centre Early Detection of Ovarian Cancer:  Autoantibodies against Mutant p53
09/13 Gregory Rice Baker IDI Heart & Diabetes Institute Phase 2 Biomarker Study of multimarker ovarian cancer diagnostics
09/14 David Huntsman British Columbia Cancer Agency SWI/SNF Mutations in Clear Cell Carcinoma
09/15 David Bowtell Peter MacCallum Cancer Centre International Cancer Genomics Consortium Study
10/01 Jessica McAlpine University of British Columbia. Academic Offices – Department of Gynaecology and Obstetrics. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy
10/02 Zhigang Wang / Ursula Matulonis Departments of Medical Oncology & Cancer Biology, Dana-Farber Cancer Institute Genetic relationships between breast and ovarian cancer: shared chromosomal alterations and response to chemotherapy
10/03 Vanessa Beesley Queensland Institute of Medical Research (QIMR) Quality of Life among women with platinum-resistant and platinum-sensitive ovarian cancer who were treated for recurrence: A Prospective Study
10/04 Aslaug Hellend Oslo University Hospital, The Norwegian Radium Hospital Copy Number changes in Serous Ovarian Carcinomas
10/05 Derek Richard Queensland Institute of Medical Research (QIMR) hSSB1 protein expression in ovarian cancer
10/06 Stuart McGregor Queensland Statistical Genetics – Queensland Institute of Medical Research (QIMR) Identifying markers of risk and outcome in ovarian cancer via efficient evaluation of DNA methylation in peripheral blood
10/07 Christopher Jones UCL EGA Institute for Women’s Health Accurate prediction of survival by aCGH analysis of ovarian tumours
10/08 Paul James FCC, Peter MacCallum Cancer A translational study to investigate the clinical significance of low penetrance breast cancer genes in a cohort of Victorian hereditary breast/ovarian cancer families
10/09 Madeleine King University of Sydney, School of Psychology A18, Brennan MacCallum Building Multi-Attribute Utility in Cancer (MAUCa): Development and valuation of cancer-specific multi-attribute health states for use in economic evaluation
10/10 William Foulkes Department of Medical Genetics, McGill University Health Centre, Montreal General Hospital Site Long Term Survivors of Advnaced Stage Heriditary Ovarian Cancer:  Molecular clues into remarkable treatment outcomes
10/11 Stephen Chanock Laboratory of Translational Genomics, Division of Cancer Genetics and Epidemiology, National Cancer Institute Deep Sequencing of 19p13
10/12 Paul Pharoah Reader in Cancer Epidemiology, Departments of Oncology and Public Health and Primary Care, University of Cambridge BRCA1/2 Germline Mutations and Ovarian Cancer Survival
10/13 Gillian Mitchell FCC, Peter MacCallum Cancer Centre Genetic Profiliing of the kConFab BRCAX cohort for selected breast cancer susceptibility loci and effect on cancer risk
10/14 Hannah Shipman Cardiff University UK. Presently:  Centre for Health & Society, Melbourne School of Population Health Consent for novel techniques in clinical practice and genetic research: Current experiences and looking ahead
10/15 Andreas Obermair Queensland Centre for Gynaecological Cancer Development of an Australian Adnexal Mass Index (AMI)
10/16 Jonathan Beesley Queensland Institute of Medical Research (QIMR) Telomerase Gene Variation in Ovarian and Breast Cancer
11/01 Clare Scott WEHI Development of a Novel Xenograft Mouse Model of High Grade Epithelial Ovarian Cancer for Analysis of Therapeutic Manipulation in order to Improve Outcomes for Patients with Ovarian Cancer
11/02 Alex Dobrovic Peter MacCallum Cancer Centre Constitutional DNA methylation in blood and its role in ovarian cancer pathogenesis
11/03 Pam Pollock IHBI, Queensland University of Technology Exome resequencing, validation of hits in large population based cohorts and xenograft model development for serous endometrial cancer
11/04 Linda Mileshkin Peter MacCallum Cancer Centre Impact of obesity on ovarian cancer – a retrospective review on the effects of obesity on chemotherapy dosing, outcomes and survival in patients with ovarian cancer
11/05 Ian Campbell Peter MacCallum Cancer Centre Genetic Analysis of mucinous ovarian tumours
11/06 David Bowtell Peter MacCallum Cancer Centre Analysis of biomarkers in ovarian cancer through the OTTA consortium
11/07 Leonie Noon University of Queensland (UQ) Factors Influencing Uptake of Genetic Services
11/08 Fergus Couch Mayo Clinic Genetic modifiers of ovarian cancer in BRCA1 mutation carriers
11/09 Anna deFazio Westmead Institute for Cancer Research, Uni of Sydney at Westmead Millennium Institute Molecular pathways from low malignant potential to invasive ovarian cancer
11/10 Elizabeth Christie Peter MacCallum Cancer Centre Identification of circulating TP53 mutations as a biomarker of high grade serous cancer
11/11 Susan Ramus University of Southern California; Department of Preventative Medicine, Harlyne Norris Tower Next generation sequencing to identify moderate risk susceptibility genes for ovarian cancer
12/01 Deborah Marsh Kolling Institute of Medial Research Investigation of a putative marker of BRCAness and drug response in epithelial ovarian cancer
12/02 Goli Samimi Garvan Institute of Medical Research TLE3 as a biomarker for taxane sensitivity in ovarian cancer
12/03 Gillian Mitchell FCC, Peter MacCallum Cancer Centre Defining the hereditary contribution to ovarian cancer:  the role of mismatch repair genes
12/04 Penny Webb Queensland Institute of Medical Research (QIMR) Vitamin D and survival from ovarian cancer
12/05 Heather Thorne FCC, Peter MacCallum Cancer Centre Investigating for the presence of a HOXB13 G84E germline variant in both familial breast and prostate cancer
12/06 Anna deFazio Westmead Institute for Cancer Research Molecular markers of relapse and treatment response in ovarian cancer
12/07 Alex Ng Brigham and Women’s Hospital Epigenetic silencing BRCA1 by C-terminal binding proteins in ovarian cancer
13/01 Orla McNally Royal Women’s Hospital (VIC) ER/PR Status in Ovarian Cancer
13/02 Huei-San Leong Peter MacCallum Cancer Centre Molecular Classifier Project
13/03 David Bowtell Peter MacCallum Cancer Centre Whole exome sequencing in ovarian cancer (ETHICS 09/38)
13/04 Jennifer Byrne Kids Research Institute, University of Sydney A novel mechanism for ATM inactivation-the role of TPD52
13/05 FCC Special requests to access GL for BRCA testing where all other avenues are closed
13/06 Graham Taylor University of Melbourne Design and Analytical Validation of an Ovarian Cancer Mutation Panel
13/07 Elizabeth Christie Peter MacCallum Cancer Centre Identification of Circulating TP53 Mutations as a Biomarker of High Grade Serous Cancer
13/08 Rachel Turner Roche Diagnostics Australian Population Data for Avastin Submission to the PBAC
13/09 Christina Annunziata National Cancer Institute, National Institutes of Health (NIH) Correlation Studies of NFKB Cooperating Proteins Among Ovarian Cancer Subtypes
13/10 Mary-Anne Young Peter MacCallum Cancer Centre Informational and support needs of AOCS participants following notification of the availability of clinically significant genetic information
14/01 Anna deFazio The Westmead Institute of Medical Research APP1086390   Carboplatin hypersensitivity: a paradigm for exploring allergy pathogenesis
14/02 Anna deFazio The Westmead Institute of Medical Research APP1084587
Title: Disclosure of Individual Research Results and Incidental Findings from Translational Tissue Bank Genomic Research: Addressing the Clinical, Ethical- legal and Logistic Complexities
14/03 David Bowtell Peter MacCallum Cancer Centre AOCS and the MOCOG Consortium
14/04 Susan Ramus University of Southern California Contribution of Rare Alleles to Ovarian Cancer
14/05 Viola Heinzelmann-Schwartz University Hospital Basel, Switzerland Effect of beta blocker on the therapy of ovarian cancer – a retrospective data base analysis
14/06 Maree Bilandzic MIMR-PHI Institute of Medical Research Profiling the Molecular Signature of the Invasive Interface: Identifying Novel Targets to Combat Ovarian Cancer Metastasis
14/07 Penny Webb QIMR Berghofer Medical Research Institute Histological and molecular subtyping of ovarian cancer
15/01 Anna deFazio The Westmead Institute of Medical Research APP 1101576
Identifying Molecular Drivers in LGS Ovarian Cancer and Developing Therapeutic Strategies for Ras-pathway Activated Subtypes
15/02 Pritinder Kaur Peter MacCallum Cancer Centre NHMRC PROJECT GRANT APP1103065 Investigating interactions between ovarian cancer cells and the mesenchymal microenvironment underlying cancer progression
15/03 Judith Clements Queensland University of Technology at the Translational Research Institute NHMRC PROJECT GRANT APP1105922 Targeting kallikrein proteases to improve treatment options for ovarian cancer
15/04 Naisana Asli Victor Chang Cardiac Research Institute NSW NHMRC PROJECT GRANT APP1108938 A Novel Approach to Characterise and Target Ovarian Cancer Stem Cells
15/05 David Bowtell Peter MacCallum Cancer Centre Understanding chemotherapy resistance in ovarian cancer
15/06 Anna deFazio The Westmead Institute of Medical Research Carcinosarcoma of the ovary: clinical epidemiology, genomics and new treatment targets
15/07 Paul Hertzog Hudson Institute of Medical Research The Role of Novel Interferon Epsilon in Ovarian Cancer
15/08 Nikola Bowden University of Newcastle Investigation of Nucleotide Excision Repair Proteins as Biomarkers of Platinum Resistance for Ovarian Cancer
15/09 Tania Moujaber The Westmead Institute of Medical Research Molecular Pathways in Low-Grade Serous Ovarian Cancer
16/01 David Bowtell in collaboration with Prof George Coukos University Hospital of Lausanne (CHUV) Characterization of the immunogenicity of high-grade serous ovarian cancer (HGSC)
16/02 Caroline Ford Lowy Cancer Research Centre, NSW NHMRC PROJECT GRANT APP1123181 Silencing the ROR: New Targets In Ovarian Cancer
16/04 Judith Clements Queensland University of Technology at the Translational Research Institute Molecular Pathways Regulating Ovarian Cancer Cell Plasticity and Stem Cell Properties
16/05 Maiken Espersen The Westmead Institute of Medical Research Clinical proteomics and personalised treatment in ovarian cancer
16/06 Masataka Takenasa Peter MacCallum Cancer Centre Identification of the predictive biomarker of chemo-sensitivity in ovarian clear cell carcinoma
16/08 Anand Jeyasekharan Cancer Science Institute of Singapore Developing strategies to target CCNE1 amplified high grade serous ovarian cancer (HGSC)
17/04 Ali Freimund Peter MacCallum Cancer Centre Sub-Optimal Outcomes In BRCA Carriers: Identifying the determinants of treatment failure in ovarian cancer patients with a BRCA1 or BRCA2 germline mutation
17/05 Rachel Delahunty Peter MacCallum Cancer Centre TRACEBACK - identification of women carrying germline BRCA1/2 mutations through a retrospective analysis of patients diagnosed with high grade ovarian cancer
17/07 Brad Nelson British Columbia Cancer Agency, Canada Unleashing the immune response against T cell-poor ovarian cancers
17/08 Tracy Crane University of Arizona, USA Symptom profiles of women participating in the Australian Ovarian Cancer Study